IRIS PubliCatt

Lorusso, Domenica
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 1.332
EU - Europa 1.254
AS - Asia 605
AF - Africa 10
SA - Sud America 6
Continente sconosciuto - Info sul continente non disponibili 1
OC - Oceania 1
Totale 3.209
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 1.322
CN - Cina 414
DE - Germania 332
SE - Svezia 261
IT - Italia 248
IE - Irlanda 129
SG - Singapore 102
UA - Ucraina 85
FR - Francia 49
RU - Federazione Russa 44
GB - Regno Unito 35
IN - India 27
FI - Finlandia 21
TR - Turchia 19
BE - Belgio 14
IR - Iran 10
JP - Giappone 10
CA - Canada 9
NL - Olanda 8
CI - Costa d'Avorio 7
ES - Italia 7
KR - Corea 7
PH - Filippine 7
CH - Svizzera 6
AT - Austria 4
CZ - Repubblica Ceca 4
CL - Cile 3
EG - Egitto 3
RO - Romania 3
VN - Vietnam 3
BR - Brasile 2
GR - Grecia 2
HK - Hong Kong 2
AE - Emirati Arabi Uniti 1
AU - Australia 1
EE - Estonia 1
EU - Europa 1
FK - Isole Falkland (Malvinas) 1
ID - Indonesia 1
MX - Messico 1
MY - Malesia 1
SA - Arabia Saudita 1
SK - Slovacchia (Repubblica Slovacca) 1
Totale 3.209
Salva come PNG Salva come JPEG
Città #
Chandler 278
Hangzhou 185
Ashburn 150
Dublin 125
Wilmington 61
Beijing 60
San Mateo 60
Singapore 59
Jacksonville 47
New York 47
Rome 43
Boston 41
Milan 41
Nanjing 41
Moscow 32
Cattolica 31
Princeton 29
Houston 22
Redwood City 20
Zhengzhou 20
Dearborn 18
Lawrence 17
Fairfield 16
Nanchang 16
Washington 16
Ann Arbor 15
Bremen 14
Izmir 13
Brussels 12
Marseille 12
Mountain View 12
Woodbridge 12
Los Angeles 11
Seattle 10
Boardman 9
Nürnberg 9
Andover 8
Busto Arsizio 8
Richardson 8
Abidjan 7
Hebei 7
Leawood 7
Cambridge 6
Paris 6
Portland 6
Redmond 6
Changsha 5
Kunming 5
Munich 5
Norwalk 5
Shenyang 5
Tianjin 5
Amsterdam 4
Antalya 4
Edinburgh 4
Guangzhou 4
London 4
Mumbai 4
Naples 4
New Haven 4
Palermo 4
Santa Clara 4
Shanghai 4
University Park 4
Vienna 4
Asti 3
Augusta 3
Bern 3
Cairo 3
Guidonia Montecelio 3
Jeju City 3
Jiaxing 3
Lappeenranta 3
Madrid 3
Martellago 3
Philadelphia 3
Sacramento 3
Sanremo 3
Toronto 3
Winnipeg 3
Ahmedabad 2
Auburn Hills 2
Bari 2
Brescia 2
Brno 2
Cavite City 2
Chicago 2
Civitavecchia 2
Coimbatore 2
Fisciano 2
Florence 2
Forest City 2
Frankfurt Am Main 2
Fremont 2
Hong Kong 2
Jinan 2
Kashan 2
Lanzhou 2
Macerata 2
Manila 2
Totale 1.840
Salva come PNG Salva come JPEG
Nome #
The MITO CERV-2 trial: A randomized phase II study of cetuximab plus carboplatin and paclitaxel, in advanced or recurrent cervical cancer 450
Carboplatin plus paclitaxel versus carboplatin plus pegylated liposomal doxorubicin as first-line treatment for patients with ovarian cancer: the MITO-2 randomized phase III trial 299
Phase III trial of gemcitabine compared with pegylated liposomal doxorubicin in progressive or recurrent ovarian cancer. 136
Sonographic imaging of urinoma 127
Phase 2 trial of nonpegylated doxorubicin (Myocet) as second-line treatment in advanced or recurrent endometrial cancer 108
Adoptive immunotherapy with cytokine-induced killer cells generated with a new good manufacturing practice-grade protocol 102
Patient-derived organoids and high grade serous ovarian cancer: from disease modeling to personalized medicine 101
Prolonged chemoradiation in locally advanced carcinoma of the uterine cervix: final results of a phase ii study (ester-1). 92
Stereotactic radiotherapy in recurrent gynecological cancer: a case series 90
Italian consensus conference on management of uterine sarcomas on behalf of S.I.G.O. (Societa' italiana di Ginecologia E Ostetricia) 90
Phase II study on weekly bolus topotecan in advanced or recurrent cervical cancer 77
Is the endometrial evaluation routinely required in patients with adult granulosa cell tumors of the ovary? 68
The immunohistochemical molecular risk classification in endometrial cancer: A pragmatic and high-reproducibility method 64
Sonographic imaging of urinoma. 63
Prospective validation study of a predictive score for operability of recurrent ovarian cancer: the Multicenter Intergroup Study DESKTOP II. A project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO 63
Building a personalized medicine infrastructure for gynecological oncology patients in a high-volume hospital 61
Development and validation of a microRNA-based signature (MiROvaR) to predict early relapse or progression of epithelial ovarian cancer: a cohort study 55
Biomarker analysis of the MITO2 phase III trial of first-line treatment in ovarian cancer: Predictive value of DNA-PK and phosphorylated ACC 53
Oregovomab: an investigational agent for the treatment of advanced ovarian cancer 53
A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms 52
Prognostic role of chemotherapy-induced neutropenia in first-line treatment of advanced ovarian cancer. A pooled analysis of MITO2 and MITO7 trials 51
Feasibility and outcome of interval debulking surgery (IDS) after carboplatin-paclitaxel-bevacizumab (CPB): A subgroup analysis of the MITO-16A-MaNGO OV2A phase 4 trial 48
Back to the future: The impact of oestrogen receptor profile in the era of molecular endometrial cancer classification 47
Emerging role of immune checkpoint inhibitors in the treatment of ovarian cancer 46
1st Evidence-based Italian consensus conference on cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal carcinosis from ovarian cancer 44
A phase I-II study of elacytarabine (CP-4055) in the treatment of patients with ovarian cancer resistant or refractory to platinum therapy 43
Diagnosis of uterine leiomyosarcoma 5 years after magnetic-resonance-guided high-intensity focused ultrasound treatment of fibroid 43
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 41
ESGO/ESTRO/ESP guidelines for the management of patients with endometrial carcinoma 41
Brain metastases in patients with EOC: Clinico-pathological and prognostic factors. A multicentric retrospective analysis from the MITO group (MITO 19) 39
Newly diagnosed ovarian cancer: Which first-line treatment? 37
Bevacizumab as maintenance treatment in BRCA mutated patients with advanced ovarian cancer: A large, retrospective, multicenter case-control study 37
Randomized controlled trial testing the efficacy of platinum-free interval prolongation in advanced ovarian cancer: The MITO-8,MaNGO, BGOG-Ov1, AGO-Ovar2.16, ENGOT-Ov1, GCIG study 36
Role of Homologous Recombination Repair (HRR) Genes in Uterine Leiomyosarcomas: A Retrospective Analysis 36
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial 35
Rucaparib versus standard-of-care chemotherapy in patients with relapsed ovarian cancer and a deleterious BRCA1 or BRCA2 mutation (ARIEL4): an international, open-label, randomised, phase 3 trial 35
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 33
Sharing real-world experiences to optimize the management of olaparib toxicities: a practical guidance from an Italian expert panel 32
Patient-Centered Outcomes in ARIEL3, a Phase III, Randomized, Placebo-Controlled Trial of Rucaparib Maintenance Treatment in Patients with Recurrent Ovarian Carcinoma 31
Cytoreductive surgery followed by chemotherapy and olaparib maintenance in BRCA 1/2 mutated recurrent ovarian cancer: A retrospective MITO group study 31
Successful pregnancy in stage IE primary non-Hodgkin's lymphoma of uterine cervix treated with neoadjuvant chemotherapy and conservative surgery 30
Olaparib as maintenance therapy in patients with BRCA 1–2 mutated recurrent platinum sensitive ovarian cancer: Real world data and post progression outcome 30
Past, present and future of adjuvant HIPEC in patients at high risk for colorectal peritoneal metastases 29
Lynch Syndrome and Gynecologic Tumors: Incidence, Prophylaxis, and Management of Patients with Cancer 29
The role of artificial intelligence in managing multimorbidity and cancer 28
null 27
The effect of age on efficacy, safety and patient-centered outcomes with rucaparib: A post hoc exploratory analysis of ARIEL3, a phase 3, randomized, maintenance study in patients with recurrent ovarian carcinoma 27
Primary results from CECILIA, a global single-arm phase II study evaluating bevacizumab, carboplatin and paclitaxel for advanced cervical cancer 27
Effect of bevacizumab in advanced low grade serous ovarian cancer: Data from the MITO 22 trial 26
PARP Inhibitors Resistance: Mechanisms and Perspectives 25
ENGOT-ov-6/TRINOVA-2: Randomised, double-blind, phase 3 study of pegylated liposomal doxorubicin plus trebananib or placebo in women with recurrent partially platinum-sensitive or resistant ovarian cancer 24
The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma 23
MEK inhibitor as single agent in low grade serous ovarian and peritoneal cancer: a systematic review and meta-analysis 23
Endometrial carcinosarcoma 23
Combining PARP inhibition and immune checkpoint blockade in ovarian cancer patients: a new perspective on the horizon? 22
Recent progress in the use of pharmacotherapy for endometrial cancer 22
Carboplatin-paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced or recurrent endometrial cancer: MITO END-2 - A randomized phase II trial 22
Morcellation worsens survival outcomes in patients with undiagnosed uterine leiomyosarcomas: A retrospective MITO group study 21
Rucaparib for patients with platinum-sensitive, recurrent ovarian carcinoma (ARIEL3): post-progression outcomes and updated safety results from a randomised, placebo-controlled, phase 3 trial 21
ESGO–ESMO–ESP consensus conference recommendations on ovarian cancer: pathology and molecular biology and early, advanced and recurrent disease 18
Health-related quality of life with pembrolizumab or placebo plus chemotherapy with or without bevacizumab for persistent, recurrent, or metastatic cervical cancer (KEYNOTE-826): a randomised, double-blind, placebo-controlled, phase 3 trial 18
Dostarlimab: From preclinical investigation to drug approval and future directions 17
Advanced and recurrent endometrial cancer: State of the art and future perspectives 17
Preclinical and Clinical Evidence of Lurbinectedin in Ovarian Cancer: Current Status and Future Perspectives 16
A common pattern of somatic mutations in t-MDS/AML of patients treated with PARP inhibitors for metastatic ovarian cancer 16
Further refining 2020 ESGO/ESTRO/ESP molecular risk classes in patients with early-stage endometrial cancer: A propensity score–matched analysis 16
Management of stage III and IVa uterine cancer 15
Late isolated subcutaneous recurrence in an endometrial cancer patient submitted to panniculectomy 14
Use of adjuvant therapy in patients with FIGO stage III endometrial carcinoma: A multicenter retrospective study 14
Lenvatinib plus Pembrolizumab for Advanced Endometrial Cancer 13
Efficacy and safety of trabectedin for the treatment of advanced uterine or ovarian carcinosarcoma: Results of a phase II multicenter clinical trial (MITO-26) 13
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 13
Chemotherapy-free treatments: Are we ready for prime time? 11
Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia ('hand-foot' syndrome) 8
Survival outcomes in patients with BRCA mutated, variant of unknown significance, and wild type ovarian cancer treated with PARP inhibitors 7
Knowledge and attitudes towards clinical trials among women with ovarian cancer: results of the ACTO study 4
New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere 3
Totale 3.702
Salva come PNG Salva come JPEG
Categoria #
all - tutte 17.613
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 17.613
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/2020422 0 0 26 23 39 62 57 42 55 36 32 50
2020/2021460 29 20 18 37 57 37 66 27 25 59 66 19
2021/2022392 32 21 10 23 24 5 11 60 15 24 61 106
2022/2023896 89 104 60 91 70 114 34 70 136 32 54 42
2023/2024762 19 197 51 48 32 108 71 13 23 35 79 86
2024/202575 35 40 0 0 0 0 0 0 0 0 0 0
Totale 3.702